Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why do women make up 71% of South Africa’s new lenacapavir users?
1+ day, 8+ hour ago (586+ words) Lenacapavir, a six-monthly HIV prevention injection, arrives in South Africa, offering renewed hope to high-risk communities and marking a major milestone in the fight against HIV. Over 55,000 people have started using lenacapavir, South Africa’s twice-yearly HIV prevention injection, since its…...
HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
1+ day, 18+ hour ago (489+ words) The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead's twice-a-year PrEP medication lenacapavir, prompting a rebuttal from several HIV charities in the UK. An evaluation committee at the watchdog said that the drug should…...
HIV risk raises concern over non-sterile injecting drug use
1+ day, 22+ hour ago (20+ words) Fijivillage Stay tuned for the latest news on our radio stations...
Treatment Action Group | 2026 Pipeline Reports: Antiretroviral therapy, PrEP, Long-acting therapies
2+ day, 4+ hour ago (82+ words) European AIDS Treatment Group Treatment Action Group | 2026 Pipeline Reports: Antiretroviral therapy, PrEP, Long-acting therapies Treatment Action Group (TAG) released three 2026 Pipeline Reports, with more to follow later this year: Each report is a comprehensive assessment on clinical trials and treatment…...
BMC Researcher Collaborates With People Who Use Drugs to Boost HIV Prevention Access - HealthCity
2+ week, 2+ day ago (441+ words) Health equity news from Boston Medical Center The goal of infectious disease physician Dr. Alysse Wurcel's work isn't simply to give clinicians more information; it's to identify the specific barriers to prescribing PrEP to people involved in the justice system…...
Injectable medication solves the problem daily pills keep creating
2+ day, 17+ hour ago (811+ words) Injectable medication prevents HIV through a long-acting shot rather than a daily tablet. Depending on the drug, a provider gives it every two months or every six months. Once you are on schedule, the medicine keeps working without any daily…...
UN programme on HIV/AIDS (UNAIDS) rolls out Lenacapavir to prevent new HIV infections in Zambia
2+ day, 18+ hour ago (609+ words) Sierra Leone Telegraph: 10 September 2026: With Zambia having received the delivery of the first US-funded HIV prevention medicine Lenacapavir, UNAIDS is now working in close partnership with the Zambian government, communities, the Global Fund to Fight AIDS, TB and Malaria and…...
Trinity College Dublin | New study reveals HIV PrEP alters immune cell function and metabolism
2+ day, 12+ hour ago (150+ words) In a new study published in the journal Frontiers in Immunology, researchers assessed the impact of PrEP on how immune cells function and use energy. To explore these effects, researchers analysed blood samples before and after treatment began, and assessed…...
NICE rejects twice-yearly HIV PrEP injection for NHS use
2+ day, 14+ hour ago (403+ words) Home News News UK A twice-yearly HIV prevention injection has not been recommended for routine NHS use in England by NICE. The draft guidance covers lenacapavir, sold by Gilead under the brand name Yeytuo, which is given every six months…...
NICE says no to Gilead's lenacapavir for HIV PrEP
2+ day, 15+ hour ago (585+ words) Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the NHS, according to initial draft guidance from reimbursement authority NICE. NICE said that the cost-effectiveness figures for lenacapavir are above the range that…...